On March 11^{th, 2008, the U.S. Food and Drug Administration (FDA) announced a warning regarding the prescription cough syrup, Tussionex Pennkinetic Extended-Release Suspension.According to the FDA, Tussionex has been linked to death and serious adverse reactions. A report released by the FDA states that Tussionex was improperly prescribed to children under the age of 6 years old and administered more frequently than recommended.}

Tussionex should only be administered in 12 hour increments. Serious side effects have been reported by those who are given the cough syrup at increments of 6 to 8 hours. Frequent administration of Tussionex can result in overdose, leading to death.

Reports of the serious side effects of Tussionex have also been reported in adults and adolescents.

The FDA is recommending the manufacturer provide clear information and labeling of Tussionex.

Defective drug attorneys are currently working on cases involving the mislabeling of prescription drugs.

This entry was posted on Tuesday, March 25th, 2008 at 9:02 pm and is filed under Defective Drugs, Medication, Overdose, Recall, Safety, Tussinex. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.